Zephyr Endobronchial Valve System
Pulmonx Corporation · Decision date Sep 11, 2026
What did the FDA approve?
The FDA recorded an approval decision dated 2026-09-11 for P180002/S032, a real-time process supplement from Pulmonx Corporation covering the Zephyr Endobronchial Valve System, product code NJK under anesthesiology. The listed statement describes changes to the funnel component of the Endobronchial Loader System included with the Zephyr 4.0-LP Endobronchial Valve, filed under change design/components/specifications/material. The supplement number establishes a link to the original P180002 approval; it does not approve the whole system anew.
The record gives no detail on the prior or revised funnel design, materials, or specifications, and no evidence of bench performance, safety, or clinical effectiveness beyond the stated purpose. The decision is a manufacturing process notice, not a new indication or trial result.
It is not established what specific change was made to the funnel component, what testing supported it, or whether any labeling changed.
FDA approval order statement
Approval for changes to the funnel component of the Endobronchial Loader System included with the Zephyr 4.0-LP Endobronchial Valve.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Anesthesiology
- Decision date
- Sep 11, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P180002/S032
- Regulatory pathway
- PMA supplement
- Applicant
- Pulmonx Corporation
- Product code
- NJK
- Decision code
- APPR
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Valve, pulmonary.
- Applicant
- Pulmonx Corporation
- Product code
- NJK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P180002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P180002 · Original PMA
Zephyr Endobronchial Valve System
P180002/S032 received
Application receipt date recorded by FDA.
P180002/S032 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P180002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Pulmonx Corporation | PMA approval | Jun 29, 2018 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Pulmonx Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 700 Chesapeake Dr., Redwood City, CA, 94063
Sources and methodology
- Original FDA record: P180002/S032
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records